Monoclonal antibody BAT6026

Phase 2Small molecule

Monoclonal antibody BAT6026 is one of 7 small molecule programs targeting Dermatitis, Atopic. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Dermatitis, AtopicActive, not recruiting

Dermatitis, AtopicPhase 2

Active, not recruiting

Competition

Competitive Landscape

8 competitors in Dermatitis, Atopic

#DrugCompanyPhaseTrials

Amlitelimab

Sanofi

Phase 3

7 2

Topical Corticosteroids

Sanofi

Phase 3

3 3

Topical Calcineurin Inhibitors

Sanofi

Phase 3

2 4

JNJ-95597528

Johnson & Johnson

Phase 2

1 5

Monoclonal antibody BAT6026

BBio-Thera Solutions

Phase 2

1 6

Calcineurin Inhibitors

Sanofi

Preclinical

2 7

Oral Corticosteroids

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Unspecified1 trial

Evaluate the Safety, Tolerability of BAT6026

Active, not recruiting·BBio-Thera Solutions·Phase 1/2·NCT06094179·33 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Monoclonal antibody BAT6026. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Monoclonal antibody BAT6026 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Monoclonal antibody BAT6026. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bio-Thera Solutions company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BBio-Thera Solutions

Monoclonal antibody BAT6026

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Unspecified1 trial

References

Drug Info

Quick Facts

Related News